Literature DB >> 8216347

NADPH-dependent enzyme-catalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide.

H K Parekh1, N E Sladek.   

Abstract

One of the metabolites found in the urine of mammals given the prodrug cyclophosphamide is alcophosphamide, an alcohol. It is most probably generated from cyclophosphamide via aldophosphamide, an aldehyde which otherwise can directly give rise to phosphoramide mustard; the latter effects the cytotoxic action of cyclophosphamide and other oxazaphosphorines. It has already been demonstrated that horse liver alcohol dehydrogenase catalyzes the reduction of aldophosphamide to alcophosphamide. Herein, we report that aldose reductase and aldehyde reductase purified from human placenta also catalyze this reaction. The Km values for aldose reductase- and aldehyde reductase-catalyzed reduction of aldophosphamide to alcophosphamide were 0.15 and 1.6 mM, respectively. Aldose reductase and aldehyde reductase accounted for 94 and 6%, respectively, of total placental pyridine nucleotide-dependent enzyme-catalyzed aldophosphamide (160 microM) reduction. Aldose reductase-catalyzed reduction of aldophosphamide appeared to be noncompetitively inhibited by sorbinil; the Ki value was 0.4 microM. The in vivo significance of these observations is uncertain but could be of some magnitude since alcophosphamide is known to be only weakly cytotoxic.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8216347     DOI: 10.1016/0006-2952(93)90669-n

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.

Authors:  M D Bacolod; S M Lin; S P Johnson; N S Bullock; M Colvin; D D Bigner; H S Friedman
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

2.  Inhibition of carboxyethylphosphoramide mustard formation from 4-hydroxycyclophosphamide by carmustine.

Authors:  S Ren; J T Slatterly
Journal:  AAPS PharmSci       Date:  1999

3.  Making a case for the socioeconomic determinacy of survival in osteosarcoma.

Authors:  Saminathan S Nathan; John H Healey
Journal:  Clin Orthop Relat Res       Date:  2013-03       Impact factor: 4.176

Review 4.  Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy.

Authors:  Navin Pinto; Susan M Ludeman; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2009-12       Impact factor: 2.533

5.  Substrate specificity of an aflatoxin-metabolizing aldehyde reductase.

Authors:  E M Ellis; J D Hayes
Journal:  Biochem J       Date:  1995-12-01       Impact factor: 3.857

6.  Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array.

Authors:  Sourav Kalra; Raman Preet Kaur; Abhilash Ludhiadch; Gowhar Shafi; Rajesh Vashista; Raj Kumar; Anjana Munshi
Journal:  Eur J Clin Pharmacol       Date:  2018-06-24       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

8.  Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia.

Authors:  Guillermo Gervasini; Jose M Vagace
Journal:  Front Genet       Date:  2012-11-22       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.